# AUTHOR QUERY FORM

Dear Author,

During the preparation of your manuscript for publication, the questions listed below have arisen. Please attend to these matters and return this form with your proof.

Many thanks for your assistance.

Query References	Query	Remarks
QI	Please confirm that given names (blue) and surnames/family names (vermilion) have been identified and spelled correctly.	
Q2	Please confirm duplicate paragraph has been deleted in abstract.	
03	References 10 and 31 are identical, hence we have deleted reference 31 and replaced with Reference citation 10 here. And subsequent references have been renumbered to maintain sequence in the text.	
Q4	Please provide the "name of the publisher" for reference 1.	
Q5	Please provide the "year of publication" for reference 8.	
Q6	Please provide the "page range" for reference 9.	
Q7	Please provide the "page range" for reference 13.	
Q8	Please provide accessed date month and year for reference 25.	

CLINICAL AND EXPERIMENTAL

# **OPTOMETRY**

## RESEARCH

# Combined passive and active treatment in strabismic amblyopia with accommodative component

Clin Exp Optom 2020

1 2

3

4

5

6

7

8

9

11

12

162

14

15

16

17

18

19

21

23

24

25

26

27

28

29

30

31

33

34

35

37

38

39

40

41

42

44

45

46

47

48

49

50

51

52

53

54

55

57

58

59

ů

Ϋ́Ε 32

No. of Pages: 10 36

Dispatch: 29-AUG-20 CE: No

Article ID

Journal Code

CXO

SPi 56

13140 43

01

DOI:10.1111/cxo.13140

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

Ainhoa Molina-Martín\* 💿 PhD Santiago Martín-González<sup>†</sup> PhD Igor Illarramendi-Mendicute<sup>‡</sup> DO Juan A. Portela-Camino<sup>§</sup> D PhD \*Department of Optics, Anatomy and Pharmacology, University of Alicante, Alicante, Spain <sup>†</sup>Department Construction and Manufacturing Engineering, University of Oviedo, Asturias, Spain <sup>‡</sup>Department of Optometry, Begitek Clinic, Donostia, Spain <sup>§</sup>Department of Optometry, Clinic Begira, Bilbao, Spain E-mail: ainhoa.molina@ua.es

Submitted: 25 October 2019 Revised: 29 June 2020 Accepted for publication: 5 August 2020 Background: Treatment of amblyopia in esotropic subjects with accommodative component currently consists of optical correction and subsequent occlusion, or penalisation, of the dominant eye. This treatment obtains a good outcome in visual acuity but poor outcomes in binocular vision. An intervention protocol that could improve the outcome of conventional treatment is presented.

Methods: A retrospective study in subjects with amblyopia associated with both fully accommodative and partially accommodative esotropia is presented. Subjects were refracted under cycloplegia and treated with occlusion (passive therapy). Subjects who did not achieve orthotropia through optical correction (partially accommodative esotropia) performed an active therapy (full-time prismatic correction and subsequent fusional vergence therapy or surgery in larger angles >12 prism dioptres). After treatment, the subjects were examined by a masked optometrist in an external ophthalmology clinic.

Results: Twenty-six subjects (12 males and 14 females) aged from six to 13 years (median 8.50; interquartile range [IQR] = 3) were included. Median age of detection was three years (IQR 1). All the subjects were hyperopic. In the baseline, median best corrected visual acuity of the amblyopic eye was 0.40 logMAR (IQR 0.30) and 0.00 logMAR (IQR 0.01) in the dominant eye. After the treatment, the median best corrected visual acuity in the amblyopic eye was 0.06 logMAR; IQR 0.08. These differences were statistically significant (p < 0.001). All subjects acquired stereoacuity equal or better than 800" with the Randot Preschool Stereoacuity Test.

Conclusions: The proposed treatment highlights the management of amblyopia in esotropic subjects with accommodative component. This treatment could help to determine if the treatment has to be passive (in fully accommodative esotropia) or a combination of passive and active therapies (in partially accommodative esotropia).

Key words: active therapy, amblyopia, esotropia, occlusion, prismation, strabismic amblyopia, strabismus, vergence therapy

Strabismic amblyopia is a neural disorder caused by a strabismus during the early critical period of development.<sup>1</sup> Consequently, active suppression in the primary visual cortex occurs to avoid cortical confusion.<sup>2</sup> Binocular presence is anecdotal among these subjects.<sup>3</sup> Difficulties in several areas such as fine motor skills<sup>4,5</sup> and reading<sup>6,7</sup> have been observed in subjects with strabismic amblyopia. These deficits are thought to be due to impaired stereopsis rather than reduced visual acuity.<sup>8,9</sup>

Clinical management of amblyopia in esotropic subjects with accommodative component currently consists of full optical correction and check-up visits to assess visual function and ocular alignment. Where the misalignment is resolved, fully accommodative esotropia is diagnosed: partially accommodative esotropia is diagnosed where partial misalignment persists. Once acuity has stabilised (two follow-up consecutive visits without visual acuity improvements), an occlusion or penalisation treatment is prescribed.<sup>10</sup> Outcomes of this conventional treatment are good in terms of improved visual acuity, but results in terms of binocular vision are only modest,<sup>11</sup> since these treatments fail to resolve either the active suppression in cases of fully accommodative esotropia, or the remaining strabismus under binocular conditions in cases of partially accommodative esotropia.

A number of authors have recently suggested that patients with strabismic amblyopia may be able to develop binocular

vision<sup>12,13</sup> and, correspondingly, intervention protocols have been shown to restore simultaneous vision. In these studies, the dominant eye signal was penalised to achieve a balanced binocular response (dichoptic stimulation).<sup>14–16</sup> Notwithstanding, the latest research suggests that, in cases where strabismus is still present, although dichoptic stimulation reduces the extent and depth of the suppression and improves binocular function (restoring simultaneous binocular perception), this recovery is very rarely accompanied by improved stereoacuity.<sup>17,18</sup>

It must also be noted that simultaneous binocular perception should only be attempted in cases where this will not result in diplopia, that is, when the cause of the

suppression has been removed, as in cases 1 2 of fully accommodative esotropia. The prob-3 lem of dichoptic stimulation in cases of par-4 tially accommodative esotropia, on the 5 other hand, is that we are only treating the 6 consequence, that is, the active suppression, 7 rather than the true cause of the suppression, that is, the remaining misalignment of 8 9 the strabismic eye. In this regard, Read et al.,<sup>19</sup> point out that normal stereoacuity 10 may require bifoveal fixation, that is, an 11 alignment within 0.6 prism dioptres 12 13 (Panum's area). Prismatic correction of the strabismic deviation, therefore, could solve 14 15 the problem, specifically in cases of partially accommodative esotropia, by providing 16 simultaneous bifoveal fixation.<sup>20</sup> The disad-17 18 vantage of such treatment, although it pro-19 vides good outcomes in subjects with 20 normal retinal correspondence (without any 21 sensory adaptations), is that the subject is 22 dependent on the prismatic correction to 23 achieve orthotropia, and no solution has yet 24 been able to fully restore binocular vision 25 without the use of prisms.

26 Our purpose in the present study is to demonstrate that stereopsis can be restored 27 28 in patients with strabismic amblyopia, specifically when associated to acquired 29 30 esotropia with accommodative component. 31 Even in those patients with partially accom-32 modative esotropia, stereopsis can be 33 restored without the dependence of pris-34 matic correction. An intervention protocol according to the patient's clinical character-35 istics was provided. A different combination 36 37 of passive and active therapies is proposed 38 to restore stereopsis according to the 39 patient's profile: fully accommodative 40 esotropia group versus partially accommo-41 dative esotropia group.

#### 43 44 Methods

Δ2

45

#### 46 Study design

The present study is a retrospective analysis
based on subjects who participated in a subsequent proof of concept study.<sup>21</sup> The study
was approved by the Basque Country Ethical Committee of Clinical Research (CEIC-E)
(Spain). Participants signed consent forms
according to the Helsinki Declaration.

54 Subjects were previously treated by other 55 practitioners with optical correction and 56 occlusion therapy before our evaluation and 57 came to a second opinion about the diagno-58 sis and treatment. Participants were rec-59 ruited and initially evaluated at two optometric centres, and were evaluated again at the end of the treatment at an ophthalmology clinic, where a masked optometrist, who was not aware of either the clinical profiles of the subjects or the previous treatment they had received, performed the final evaluation.

#### Subjects

Study subjects were chosen according to the following selection criteria: subjects with amblyopia previously treated with optical correction and occlusion, difference in logMAR acuity of  $\geq 2$  lines, best corrected visual acuity (BCVA) < 0.10 logMAR, and horizontal strabismus diagnosed with the Unilateral Cover Test and accommodative stimulus. In addition, only subjects with normal retinal correspondence (fusion at objective angle in peripheral slides with synoptophore) were included. Subjects with non-comitance (near-distance angle  $\geq 5$ prism dioptres  $[\Delta]$ ) due to accommodative esotropia with high accommodative convergence/accommodation ratio (AC/A), hypermetropic anisometropia > 3 D (spherical equivalent [SE]) if corrected with spectacles (to prevent aniseikonia), ocular pathology, strabismic surgery, vertical deviations, nystagmus and cognitive delay were excluded from the study.

#### **Clinical evaluation**

Visual evaluation included: best corrected distance visual acuity using an Early Treatment Diabetic Retinopathy Study-format logarithmic visual acuity chart (logMAR acuity) with a SIFIMAV Vision Tester; Unilateral Cover Test using accommodative stimuli to determine the presence of strabismus; refractive error by automated refractor under cycloplegia (cyclopentolate 1% and Topcon model TRK 1P); and evaluation of the anterior and posterior segment.

Binocular vision was evaluated using the Worth Four-Dot test and a projector at a distance of four metres in the dark. The results of the test were classified under fusion, suppression and diplopia. A synoptophore (Oculus, Germany) was used to evaluate the fusion capacity at the objective angle of deviation (normal retinal correspondence).

Stereoacuity measurements were analysed according to two different tests. The first was the Randot Preschool Stereoacuity Test (RPST; Stereo Optical, Inc., Chicago, IL, USA); if responses indicated nil stereopsis, stereoacuity was then evaluated with the TNO test (Lameris Intrumenten, Groenekan, The Netherlands) using the first60plates (Pages III, IV and V). The manufac-61turers do not provide the stereoacuity value62of these plates; an arbitrary measure of631,200" was therefore assigned to obtain a64quantifiable value.65

66

67

78

79

94

95

109

110

115

116

#### Treatment

The treatment included passive therapy and 68 active therapy strategies, following the 69 Suttle revision:<sup>22</sup> passive therapy includes 70 forms of treatment which require no action 71 from the patient; whereas active therapy 72 requires the patient's active participation. 73 Figure 1 summarises the treatment received **F**74 by the participants between the baseline 75 and the final evaluation. 76 77

#### PASSIVE THERAPY Optical Correction

Treatment began by determining the 80 patient's optimal optical correction under 81 cycloplegia. Refractive errors were corrected 82 following the Paediatric Eye Disease Investi-83 gator Group (PEDIG)<sup>22</sup> with full sphere and 84 cylinder correction under cycloplegia. One 85 month after prescription, the participants' 86 visual acuity and strabismic deviation were 87 checked. If visual acuity of the amblyopic 88 eye improved, the patient was then evalu-89 ated again three months later. If visual acu-90 ity of the amblyopic eye did not improve at 91 two successive check-ups, then occlusion 92 was prescribed. 93

#### Occlusion


Participants were occluded following the 96 PEDIG criteria: six hours in cases of severe 97 amblyopia<sup>23</sup> (visual acuity 0.8 to 1.0 98 logMAR at baseline), and two hours in 99 cases of moderate and mild amblyopia<sup>24</sup> 100 (visual acuity 0.1 to 0.7 at baseline). 101 Trimestral check-ups were scheduled at 102 the centres which conducted the visual 103 acuity and binocular vision tests (Worth 104 Four-Dot test and stereoacuity). Occlusion 105 was discontinued when the participant 106 achieved a minimum logMAR visual acuity 107 of 0.10 in the amblyopic eye. 108


#### ACTIVE THERAPY

If the strabismic deviation was present after111optical correction (partially accommodative112esotropia), the subject received complemen-113tary active therapy treatment.114

#### MONOCULAR THERAPY

During the occlusion period, participants 117 had to perform activities that demanded 118





their attention. In addition, participants were cited at the optometric centre one day a week to perform supervised active therapy by an optometrist. These procedures consisted of exercises involving accommodative and anti-suppression therapy follow-54 ing 'In-office Vision Therapy Manual of Procedures'<sup>25</sup> proposed by PEDIG.<sup>26</sup> The 55 suppression was only treated in patients 56 57 with normal retinal correspondence where 58 the cause of the misalignment was able to be resolved with prisms. 59

#### PRISMATIC CORRECTION AND FUSIONAL **VERGENCE THERAPY**

Magnitude of prismatic correction was obtained using the Unilateral Cover Test, accommodative stimulus (visual acuity two lines higher than amblyopic visual acuity) and a prism placed in front of the dominant eye. All the magnitude was corrected. All subjects showed normal retinal correspondence, indicating that prismatic correction also provided simultaneous vision. Fresnel prisms were used in all cases.

In subjects with esotropia  $\leq 12$  prism 60 dioptres ( $\Delta$ ), the prismatic correction was 61 placed in front of the dominant eve. Where 62 the esotropic deviation was >  $12\Delta$ , the pris-63 matic correction was split between both eyes 64 with the following criteria: the prismatic 65 power in front of the dominant eye would be 66 twice that in front of the amblyopic eye. A 67 prism adaptation test was then performed to 68 assess the viability of the prismatic correc-69 tion.<sup>27</sup> This procedure consisted of testing if 70 the subject tolerated the prism or the devia-71 tion appeared after a period of time. These 72 subjects were required to wear the prismatic 73 correction on a full-time basis.<sup>28</sup> 74

Since all subjects achieved binocular vision 75 with the prism correction, treatment was com-76 plemented with fusional vergence therapy 77 using a computer program in Random Dot 78 format with anaglyph glasses (VisionBuilder 79 Version 2.7 for Windows, Haraldseth Software, 80 Hamar, Norway). VisionBuilder has two pro-81 gram versions, Office and Home. We used the 82 Office version to measure negative fusional 83 vergence at both optometric centres; and the 84 Home version to strengthen negative and pos-85 itive fusional vergence in the patient's home. 86 In both cases, the distance was set to 40 cm, 87 88 and participants were required to do the exercises at home for 16 minutes a day, five days 89 a week. 90

Fusional vergence exercises (convergence 91 or divergence) followed the same procedure 92 with opposite disparity. A random dot cross 93 shape with a hidden circle was presented at 94 zero disparity (Figure 2). Stereoscopic **■**95 demand and dot size were adjusted to 96 ensure the patient was able to perceive the 97 position of the hidden circle. Each time the 98 patient selected the right answer, the ver-99 gence demand (positive or negative) was 100 increased by one step. When the patient 101 selected an incorrect answer, the vergence 102 demand was reduced by four steps. 103

Fusional vergence therapy using the computer at home was complemented with monthly sessions at the optometric centres. Different orthoptic instruments (anaglyphic slides, vectograms and stereoscopes) were used at these sessions.<sup>26</sup> In addition, binocular vision at the objective angle was stimulated with the synoptophore.

#### **PROGRESSIVE REDUCTION OF PRISMATIC POWER AND SURGERY**

In participants with a strabismic angle  $\leq 12\Delta$ , a progressive reduction of prismatic power 116 was performed. The following criteria to 117 change the prismatic correction were chosen: 118

104

105

106

107

108

109

110

111

112

113

114




Figure 2. Logical process of the game. The subject has to pinpoint a ball which is situated on one of the four extremes of a cross (top, bottom, right or left). The program automatically adjusts the vergence difficulty during the training session. If the patient's response is correct, the software will split the image into two anaglyph crosses which the subject must merge using their own vergence system. If the patient fails to respond correctly, the two crosses are merged by the program.

2 a change in the prismatic power was consid-3 ered when the subject was able to diverge ≥ 4∆ over their prismatic correction with the 5 computer software. The amount of prismatic 6 reduction was equal to half the divergence 7 capacity. For example, if a participant with 8 esotropia compensated with an 8∆ Fresnel 9 prism was able to diverge 6∆, the new Fres-10 nel prism would be 5∆. The Fresnel prism 11 was then changed, and the participant had to 12 achieve orthotropia with the new prismatic 13 correction. The ultimate objective was to 14 achieve orthotropia without any prismatic 15 correction.

In subjects with a larger strabismus angle  $(> 12\Delta)$ , surgery was required to eliminate 48 prismatic correction. The ultimate objective 49 of the fusional vergence therapy was to 50 obtain a fusional vergence range of around 51  $10\Delta$  before surgery. Surgical planning took into account the prismatic correction (stable 52 53 deviation angle) and the vergence amplitude 54 (capacity to compensate the post-surgical deviation). 55

#### 57 Statistical analysis

58 Statistical analysis of the results was per-59 formed using SPSS for Windows, Version 19.0 (SPSS Inc., Chicago, IL, USA). According to the Kolmogorov–Smirnov test, the studied parameters followed a non-normal distribution, and non-parametric tests were therefore applied. All descriptive variables were presented as median  $\pm$  interquartile range (IQR). All statistical tests were two-tailed, and findings were considered significant at p < 0.05.

Comparisons between pre- and postrefraction, pre- and post-treatment outcomes have been analysed by the Wilcoxon test. An additional comparison between groups (occlusion alone versus occlusion plus active therapy) was analysed by the Mann-Whitney test.

The effectiveness of the proposed treatment was evaluated by means of objective refraction, BCVA and stereoacuity. To better analyse binocular vision changes, binocular function (BF) was used to describe the degree of binocularity, as proposed by Webber et al.<sup>29</sup> If stereopsis was not measurable on the Random Dot test but the child did not suppress on the Worth Four-Dot test (that is, they reported four lights), a log threshold of four was recorded. If the child reported only two red or three green

lights on the Worth Four-Dot test, they were 60 deemed to have complete suppression 61 (recording a log threshold score of five). 62 Assigning a value to represent the presence 63 or absence of suppression in this way, 64 enabled the inclusion of all participants in 65 the analysis of BF as an extension of the 66 stereoacuity scale. 67

> 68 69

> 70

71

72

107

109

110

**T**108

#### Results

#### **Baseline**

All the subjects included in the present 73 study were diagnosed with strabismic 74 amblyopia at the baseline examination, that 75 is, all subjects presented with strabismus 76 even when wearing their spectacles. Con-77 stant esotropia was present in all subjects 78 and, consequently, unilateral amblyopia of 79 the non-dominant eve. 80

The sample size was 26 subjects (12 boys 81 and 14 girls) aged from six to 13 years 82 (median 8.50; IQR 3). The median age of 83 detection was three years (IQR 1). All sub-84 jects were diagnosed with strabismic ambly-85 opia, eight of them also presenting 86 anisometropia. Hyperopia was present in all 87 subjects. The median spherical refraction in 88 spherical dioptres (D) of the amblyopic eye 89 was +3.75 D (IQR 2.19) and the median 90 spherical refraction of the dominant eye 91 was +3.00 D (IQR 2.69). The median BCVA of 92 the amblyopic eye was 0.40 logMAR (IQR 93 0.30) and 0.00 logMAR (IQR 0.01) in the 94 95 dominant eye.

The median esotropia deviation was  $4\Delta$ 96 (IQR 3). None of the subjects had binocular 97 vision at the baseline examination using the 98 Worth Four-Dot test (five subjects showed 99 diplopia and 21 subjects showed suppres-100 sion). Accordingly, none of the subjects 101 showed stereoacuity with either the TNO 102 test or the RPST. The BF values assigned to 103 each subject varied from 4.00, in subjects 104 with diplopia, to 5.00 in those with suppres-105 sion, with a median value of 5.00. 106

The clinical characteristics of each subject at the baseline are summarised in Table 1.

#### Post-treatment evaluation

After the treatment, all subjects were exam-111 ined by an external optometrist at the oph-112 thalmology clinic. Analysis of the data 113 showed an improvement in the BCVA of the 114 amblyopic eye in all subjects, from baseline 115 evaluation (median value of 0.40 logMAR) to 116 final evaluation (median 0.06 logMAR; IQR 117 0.08). These differences were statistically 118

۷o.		Age	Age at detection	Type of amblyopia	Refraction SE	BCVA	Δ	Worth Four-Dot test	Stereoacuity	BF
I	Dominant	13	2	Strabismic	4.25	0.00	8	Suppression	Null	5
	Amblyopic				4.25	0.52				
2	Dominant	8	2	Strabismic	4.75	-0.04	8	Diplopia	Null	4
	Amblyopic				5.50	0.40				
3	Dominant	12	2	StrabismicAnisometropia	1.75	0.00	6	Suppression	Null	5
	Amblyopic				3.00	0.52				
1	Dominant	9	3	StrabismicAnisometropia	1.00	-0.04	6	Suppression	Null	5
	Amblyopic				1.88	0.40				
5	Dominant	8	4	StrabismicAnisometropia	1.25	-0.08	2	Suppression	Null	5
	Amblyopic				3.75	0.40				
5	Dominant	6	4	StrabismicAnisometropia	3.25	0.00	30	Suppression	Null	5
	Amblyopic				3.25	0.70				
7	Dominant	8	3	StrabismicAnisometropia	2.50	0.07	5	Suppression	Null	5
	Amblyopic				3.75	0.30				
3	Dominant	8	3	Strabismic	5.88	0.00	4	Diplopia	Null	4
	Amblyopic				5.50	0.40				
)	Dominant	7	3	StrabismicAnisometropia	1.25	0.00	2	Suppression	Null	5
	Amblyopic				3.25	0.70				
10	Dominant	9	3	StrabismicAnisometropia	1.50	0.02	2	Suppression	Null	5
	Amblyopic		2		4.25	0.70				-
11		8	3	Strabismic	0.63	0.10	4	Suppression	Null	5
	Amblyopic	Ũ	2		0.88	0.70	·			
12	Dominant	6	3	Strabismic	3.13	0.00	4	Suppression	Null	5
	Amblyopic	U	5		4.38	0.70	7	55ppi 655/6/1		5
13	Dominant	9	2	Strabismic	7.50	0.00	35	Diplopia	Null	4
	Amblyopic	2	2	Strabistific	7.63	0.40	55	Брюріа	Null	-
14	5.	10	2	Strabismic	6.50	0.40	30	Suppression	Null	5
	Amblyopic	10	2	Strabistific	6.50	0.00	50	Suppression	Null	J
15	Dominant	6	3	Strabismic	3.00	0.40	40	Suppression	Null	5
15		0	2	Stradistric	3.00	0.00	40	Suppression	INUII	5
16	Amblyopic	11	3	Strahismis			c	Suppression	NIGH	5
10	Dominant	11	5	Strabismic	0.13	0.00	0	Suppression	Null	Э
	Amblyopic	11	h	Ctuchionsia	0.50	0.40	4	Cummunation	NI. II	-
17		11	2	Strabismic	3.50	-0.08	4	Suppression	Null	5
	Amblyopic	~	2	Chuckiensie Arsie sussetuur i	3.50	0.52	~	Current and a state	NIGH	_
ŏ		6	2	StrabismicAnisometropia	2.00		6	Suppression	Null	5
	Amblyopic	1.4	4	Ctuchions's	2.00	0.40	2	Cummunation	NIGH	_
9	Dominant	11	4	Strabismic	2.00	-0.04	2	Suppression	Null	5
	Amblyopic	-	-		1.75	0.30		<b>C</b> .	N. 11	_
20		8	2	Strabismic	2.00	0.00	4	Suppression	Null	5
	Amblyopic				5.00	0.40		<b>.</b> .		
21		11	2	Strabismic	5.00	0.00	4	Suppression	Null	5
	Amblyopic				5.00	0.70				
22	Dominant	7	3	Strabismic	4.00	-0.04	4	Diplopia	Null	4
	Amblyopic				4.00	0.40				
23		8	2	Strabismic	2.25	0.00	2	Suppression	Null	5
	Amblyopic				2.25	0.70				
24	Dominant	13	4	Strabismic	4.00	0.00	4	Diplopia	Null	4
	Amblyopic				4.00	0.70				
25	Dominant	12	2	Strabismic	6.25	0.10	4	Suppression	Null	5

 $^{58}_{59}$  Table 1. Baseline clinical parameters. The BCVA is shown in logMAR acuity and stereoacuity in second arc

No.	Age	e Age at detection	Type of amblyopia	<b>Refraction SE</b>	BCVA	Δ	Worth Four-Dot test	Stereoacuity	BF
Ambly	opic			6.88	0.40				
26 Domir	nant 12	3	Strabismic	3.00	0.00	2	Suppression	Null	5
Ambly	opic			3.50	0.50				
AE: amblyo matic diop		BCVA: Best Co	prrected Visual Acuity, E	3F: Binocular Functio	on, DE: d	domi	nant eye, SE: spherical	equivalent, Δ: ι	pris-

#### Table 1. Continued

1 2

3

4

5 6

7

8

9

10

11

12

21

significant (p < 0.001). Binocular vision also</li>
improved in all subjects as a result of the
treatment, from a BF median value of 5.00
to 2.60 (IQR 0.30) and these differences
were statistically significant (p < 0.001).</li>

18 Each treatment was independently
19 analysed to determine the therapeutic effec
20 of the different treatments.

#### 22 REFRACTION

Following the baseline examination, objec-23 tive refraction was obtained by means of 24 cycloplegia. The mean spherical positive and 25 astigmatism were found to be hypo-26 corrected in 10 of the 26 subjects. Then, the 27 maximum positive was prescribed to all 28 subjects. The median spherical refraction of 29 the amblyopic eye was found to be + 4.25 D 30 (IQR 2.50) and + 3.37 D (IQR 3.44) in the 31 32 dominant eye. Comparing the spherical 33 refraction obtained at baseline and postrefraction examinations, statistically signifi-34 cant differences were found in both ambly-35 opic (p = 0.002) and dominant eyes 36 (p = 0.008). 37

With the new prescription, the BCVA of 38 the amblyopic eye improved in some sub-39 jects. The median value was 0.40 logMAFT 40 41 (IQR 0.15) compared to the baseline visual acuity (0.40 logMAR; IQR 0.30), these differ-Δ2 ences being statistically significant (p = 0.01). 43 In the dominant eye, the new prescription 44 was the same in most of the subjects with a 45 median value of 0.00 logMAR (IQR 0.01), 46 47 indicating no significant variation from the 48 baseline value (p = 0.32).

The mean esotropia was also significantly 49 prescription reduced with the new 50 (p = 0.002), to a median deviation of  $4\Delta$  (IQR 51 7). In some subjects, strabismus was absent 52 with the new prescription, and these sub-53 jects were therefore diagnosed as having 54 acquired fully accommodative esotropia. In 55 other subjects, the esotropic angle persisted 56 despite full hyperopia correction, and these 57 subjects were diagnosed with acquired par-58 tially accommodative esotropia. Binocular 59

vision improved with the new prescription in one subject, who achieved stereoacuity of 1,200". No significant differences in BF were found with the new prescription (p = 0.32).

The clinical characteristics of each subject with the new prescription are summarised in Table 2.

#### OCCLUSION

Occlusion therapy was prescribed to subjects with fully accommodative esotropia. The duration of the occlusion treatment varied for each individual, with a median duration of six months (IQR 3). After the occlusion, the median BCVA of the amblyopic eye improved in all subjects from 0.35 logMAR (IQR 0.25) to 0.05 logMAR (IQR 0.01). These differences were statistically significant (p = 0.01) when compared to the postrefraction BCVA. Binocular vision also improved in all subjects with the occlusion. All subjects showed stereoacuity below 800", with a median BF of 2.60 (IQR 0.23) compared to a post-refraction BF median of 5.00 (IQR 1).

The clinical characteristics of each subject after the treatment are summarised in Table 3 (subjects 19 to 26).

#### **OCCLUSION AND ACTIVE THERAPY**

Occlusion combined with active therapy was performed in subjects with partially accommodative esotropia. The median duration of the treatment was four months (IQR 0). The outcomes showed an improvement of BCVA in the amblyopic eye, from a post-refraction median value of 0.40 logMAR (IQR 0.30) to 0.07 logMAR (IQR 0.06) post-treatment. These differences were statistically significant (p < 0.001). The median BF also improved after the treatment, from a post-refraction median value of 5.00 (IQR 0) to 2.90 (IQR 0.30). All subjects showed stereoacuity below 800" with RPST. The partially accommodative esotropia group presented binocular vision with the use of prismatic correction with a median deviation of  $6\Delta$  (IQR 12).

The second purpose of treatment was 72 to achieve orthotropia without the use of 73 prisms. With this objective, surgery was 74 prescribed for subjects with a deviation 75 of >  $12\Delta$ , while fusional vergence therapy 76 was applied to reduce the prismatic cor-77 rection in subjects with a deviation of 78  $< 12\Delta$ . Improvements in vergence values 79 at each session were not recorded, nor 80 was the number of the sessions needed. 81 Treatment was deemed complete in each 82 case when the subject was able to 83 achieve orthotropia without prismatic 84 correction. 85

60

61

62

63

65

66

67

68 69

70

71

86

87

88

89

90

91

92

93

The clinical characteristics of each subject post-treatment are summarised in Table 3 (subjects 1 to 18).

#### Acquired fully accommodative esotropia and acquired partially accommodative esotropia treatment

As stated above, patients were treated 94 according to the type of esotropia they pres-95 ented. Fully accommodative esotropia sub-96 jects were treated using occlusion; whereas 97 subjects with remaining esotropia after full 98 hyperopia correction (partially accommoda-99 tive esotropia group) were treated using 100 occlusion and active therapy. 101

The post-refraction median BCVA of the 102 amblyopic eye for the fully accommodative 103 esotropia group was 0.35 logMAR (IQR 104 0.25), and 0.40 logMAR (IQR 0.30) for the 105 partially accommodative esotropia group, 106 with statistically significant differences 107 between them (p = 0.03). Esotropia had a 108 median value of  $0\Delta$  in the fully accommo-109 dative esotropia group and  $4.50\Delta$  (IQR 10) 110 in the partially accommodative esotropia 111 group, with statistically significant differ-112 ences between them (p < 0.001). The 113 median BF was 5.00 (IQR 1) in the fully 114 accommodative esotropia group and 5.00 115 (IQR 0) in the partially accommodative 116 esotropia group, with no statistical differ-117 ences between them (p = 0.21). 118

The post-treatment median BCVA of the amblyopic eye for fully accommodative esotropia group was 0.05 logMAR (IQR 0.1), and 0.07 logMAR (IQR 0.06) for the partially accommodative esotropia group, with no statistical differences between them (p = 0.63). Esotropia was absent in all groups. The median BF was 2.60 (IQR 0.23) in the fully accommodative esotropia group and 2.90 (IQR 0.30) in the partially accommodative esotropia group, with no statistical differences between them (p = 0.09).

#### Discussion

1

2

3

4 5

6 7

8

9

10

11

12 13 14

15 16

03

Treatment for strabismic amblyopia<sup>30</sup> is 17 currently split into two types of passive 18 19 therapy: full cycloplegic refraction followed 20 by a prolonged period of spectacle wear, and subsequently by occlusion therapy to 21 improve visual acuity outcomes.<sup>10</sup> Cotter 22 et al.<sup>31</sup> demonstrated that optical treat-23 ment alone produced substantial therapeu-24 25 tic effects in many children with amblyopia 26 (amblyopia was resolved in 34% of the 27 sample). In fully accommodative esotropia subjects, full correction improves visual 28 29 acuity and achieves ocular alignment, 30 restoring binocular vision in most cases. 31 However, in cases of partially accommoda-32 tive esotropia and non-accommodative 33 esotropia, full correction improves visual acuity but fails to achieve ocular alignment, 34 35 and cortical mechanisms such as anomalous retinal correspondence and inter-36 37 ocular suppression are employed to eliminate the unwanted consequences of 38 39 confusion and diplopia.<sup>10</sup>

40 The present study shows that, in the 41 fully accommodative esotropia group, this 42 intervention protocol achieves good out-43 comes in terms of visual acuity and restoration of binocular vision. Full correction 44 45 enabled full ocular alignment, rendering 46 cortical mechanisms to eliminate confu-47 sion and diplopia unnecessary. At base-48 line, subjects with fully accommodative 49 esotropia did not wear the correct optical 50 prescription and were previously diag-51 nosed with partially accommodative 52 esotropia. Treatment in the partially 53 accommodative esotropia group was a 54 more complex proposition for practi-55 tioners that, in some cases, was resolved 56 with a good refractive correction. Prescrip-57 tion error may condition the diagnosis 58 making cycloplegic refraction an essential eoacuity in second arc 59

1         Dominant         4.25         0.00         8         Suppression         Null         5           2         Dominant         4.75         0.04         Null         4           3         Dominant         1.75         0.00         6         Suppression         Null         5           4         Dominant         1.00         -0.04         6         Suppression         Null         5           5         Dominant         1.00         -0.08         2         Suppression         Null         5           6         Dominant         3.25         0.00         30         Suppression         Null         5           7         Dominant         3.25         0.07         5         Suppression         Null         4           9         Dominant         1.25         0.00         4         Diplopia         Null         5           10         Dominant         1.25         0.00         2         Suppression         Null         5           10         Dominant         1.25         0.00         2         Suppression         Null         5           10         Dominant         1.50         0.00         2	No	L.	Refraction SE	BCVA	Δ	Worth Four-Dot test	Stereoacuity	BF	60 61
Amblyopic         4.25         0.52           2         Dominant         4.75         -0.04         8         Dippia         Null         4           3         Dominant         1.75         0.00         6         Suppression         Null         5           4         Dominant         1.00         -0.04         6         Suppression         Null         5           5         Dominant         1.25         -0.08         2         Suppression         Null         5           6         Dominant         2.25         0.70         7         Suppression         Null         5           7         Dominant         2.50         0.07         5         Suppression         Null         4           Amblyopic         3.25         0.70         7         Suppression         Null         5           9         Dominant         1.50         0.02         2         Suppression         Null         5           11         Dominant         1.50         0.02         2         Suppression         Null         5           12         Dominant         1.50         0.02         2         Suppression         Null         5							-		62
2         Dominant         4.75         -0.04         8         Diplopia         Null         4           Amblyopic         5.50         0.40         5         0.40         5           3         Dominant         1.75         0.00         6         Suppression         Null         5           4         Dominant         1.00         -0.04         6         Suppression         Null         5           5         Dominant         1.25         -0.08         2         Suppression         Null         5           6         Dominant         3.25         0.00         30         Suppression         Null         5           7         Dominant         3.25         0.07         5         Suppression         Null         5           8         Dominant         3.25         0.07         2         Suppression         Null         4           8         Dominant         5.05         0.40         2         Suppression         Null         5           9         Dominant         1.50         0.02         2         Suppression         Null         5           10         Dominant         1.50         0.00         30	-				-			-	63
Amblyopic         5.50         0.40           3         Dominant         1.75         0.00         6         Suppression         Null         5           4         Dominant         1.00         -0.04         6         Suppression         Null         5           5         Dominant         1.25         -0.08         2         Suppression         Null         5           6         Dominant         3.25         0.07         5         Suppression         Null         5           7         Dominant         2.50         0.07         5         Suppression         Null         5           7         Dominant         5.80         0.40         4         Diplopia         Null         4           7         Dominant         5.80         0.40         4         Diplopia         Null         5           8         Dominant         1.25         0.00         2         Suppression         Null         5           9         Dominant         1.50         0.02         2         Suppression         Null         5           10         Dominant         1.50         0.00         35         Diplopia         Null         5	2				8	Diplonia	Null	4	64
Interpret         Interpret         Summart         Interpret         Summart         Interpret           3         Dominant         1.00         -0.04         6         Suppression         Null         5           4         Dominant         1.25         -0.08         2         Suppression         Null         5           5         Dominant         1.25         -0.08         2         Suppression         Null         5           6         Dominant         3.25         0.07         5         Suppression         Null         5           7         Dominant         2.50         0.07         5         Suppression         Null         4           8         Dominant         5.80         0.00         4         Diplopia         Null         4           9         Dominant         1.25         0.00         2         Suppression         Null         5           4         Dominant         1.50         0.02         2         Suppression         Null         5           10         Dominant         1.50         0.02         2         Suppression         Null         5           11         Dominant         1.50         0.00	-				Ũ	Dipiopia		•	65
Amblyopic       3.00       0.52         4       Dominant       1.00      0.46       6       Suppression       Null       5         5       Dominant       1.25      0.08       2       Suppression       Null       5         6       Dominant       3.25       0.00       30       Suppression       Null       5         7       Dominant       2.50       0.07       5       Suppression       Null       4         Amblyopic       3.75       0.40       6       Dominant       5       3         8       Dominant       5.80       0.00       4       Diplopia       Null       4         9       Dominant       1.25       0.00       2       Suppression       Null       5         10       Dominant       1.50       0.02       2       Suppression       Null       5         10       Dominant       1.50       0.02       2       Suppression       Null       5         11       Dominant       1.50       0.02       Suppression       Null       5         12       Dominant       1.50       0.00       30       Suppression       Null       5	2	5 1			6	Suppression	Null	5	66
4       Dominant       1.00       -0.04       6       Suppression       Null       5         5       Dominant       1.25       -0.08       2       Suppression       Null       5         6       Dominant       3.25       0.00       30       Suppression       Null       5         7       Dominant       2.50       0.07       5       Suppression       Null       5         7       Dominant       2.50       0.07       5       Suppression       Null       4         7       Dominant       5.50       0.40       9       Dominant       1.50       0.02       2       Suppression       Null       5         9       Dominant       1.50       0.02       2       Suppression       Null       5         11       Dominant       0.63       0.10       4       Suppression       Null       5         12       Dominant       7.50       0.00       30       Suppression       Null       5         13       Dominant       7.50       0.00       30       Suppression       Null       5         14       Dominant       7.50       0.00       30       Suppression	5				0	Suppression	Null	J	67
Amblyopic       1.88       0.40         5       Dominant       1.25       -0.08       2       Suppression       Null       5         6       Dominant       3.25       0.00       30       Suppression       Null       5         7       Dominant       5.50       0.00       4       Diplopia       Null       4         Amblyopic       3.75       0.30       -       -       -       7         8       Dominant       5.88       0.00       4       Diplopia       Null       4         4       Amblyopic       5.50       0.40       -       -       -       7         9       Dominant       1.25       0.00       2       Suppression       Null       5       -         10       Dominant       1.50       0.02       2       Suppression       Null       5         11       Dominant       1.50       0.02       2       Suppression       Null       5         12       Dominant       7.50       0.00       30       Suppression       Null       4         13       Dominant       5.50       0.00       30       Suppression       Null <t< td=""><td>4</td><td>5 1</td><td></td><td></td><td>c</td><td>Cupprocion</td><td>NILL</td><td>F</td><td>68</td></t<>	4	5 1			c	Cupprocion	NILL	F	68
5         Dominant         1.25         -0.08         2         Suppression         Null         5           6         Dominant         3.25         0.40         Suppression         Null         5           7         Dominant         2.50         0.07         5         Suppression         Null         5           8         Dominant         2.50         0.07         5         Suppression         Null         4           9         Dominant         1.25         0.00         2         Suppression         Null         5           9         Dominant         1.25         0.00         2         Suppression         Null         5           10         Dominant         1.50         0.00         2         Suppression         Null         5           11         Dominant         0.63         0.10         4         Suppression         Null         5           12         Dominant         1.50         0.00         35         Diplopia         Null         4           13         Dominant         5.0         0.00         30         Suppression         Null         5           14         Dominant         5.50         0	4				0	Suppression	Null	5	69
Amblyopic       3.75       0.40         6       Dominant       3.25       0.00       30       Suppression       Null       5         7       Dominant       2.50       0.07       5       Suppression       Null       5         8       Dominant       5.88       0.00       4       Diplopia       Null       4         Amblyopic       3.75       0.30       2       Suppression       Null       4         9       Dominant       5.50       0.00       2       Suppression       Null       5         10       Dominant       1.50       0.02       2       Suppression       Null       5         11       Dominant       0.63       0.10       4       Suppression       Null       5         12       Dominant       3.13       0.00       4       Suppression       Null       5         13       Dominant       7.50       0.00       30       Suppression       Null       5         14       Dominant       6.50       0.00       30       Suppression       Null       5         15       Dominant       5.50       0.30       Suppression       Null       5 </td <td>-</td> <td>5 1</td> <td></td> <td></td> <td>2</td> <td>C</td> <td>N I. JI</td> <td>-</td> <td>70</td>	-	5 1			2	C	N I. JI	-	70
6         Dominant         3.25         0.00         30         Suppression         Null         5           7         Dominant         2.50         0.07         5         Suppression         Null         5           8         Dominant         5.88         0.00         4         Diplopia         Null         4           Amblyopic         5.50         0.40         -         -         7           9         Dominant         5.88         0.00         2         Suppression         Null         4           Amblyopic         5.50         0.40         -         -         -         7           10         Dominant         1.50         0.02         2         Suppression         Null         5           Amblyopic         4.25         0.70         -         -         -         -           11         Dominant         1.50         0.02         2         Suppression         Null         5           4         Dominant         3.13         0.00         35         Diplopia         Null         5           13         Dominant         6.50         0.40         -         -         -           4	5				2	Suppression	NUII	5	71
Amblyopic       3.25       0.70       5       Suppression       Null       5         7       Dominant       2.50       0.07       5       Suppression       Null       4         8       Dominant       5.88       0.00       4       Diplopia       Null       4         9       Dominant       1.25       0.00       2       Suppression       Null       5         10       Dominant       1.50       0.02       2       Suppression       Null       5         11       Dominant       0.63       0.10       4       Suppression       Null       5         12       Dominant       0.63       0.10       4       Suppression       Null       4         13       Dominant       7.50       0.00       35       Diplopia       Null       4         4       Dominant       6.50       0.00       30       Suppression       Null       5         14       Dominant       5.50       0.30       Interssion       Null       5         15       Dominant       5.00       0.00       4       Suppression       Null       5         14       Dominant       6.50	_	5 1						_	72
7       Dominant       2.50       0.07       5       Suppression       Null       5         8       Dominant       5.88       0.00       4       Diplopia       Null       4         9       Dominant       1.25       0.00       2       Suppression       Null       5         9       Dominant       1.50       0.02       2       Suppression       Null       5         10       Dominant       1.50       0.02       2       Suppression       Null       5         11       Dominant       0.63       0.10       4       Suppression       Null       5         12       Dominant       3.13       0.00       4       Suppression       Null       5         13       Dominant       7.50       0.00       30       Suppression       Null       5         14       Dominant       6.50       0.40       -       -       -         14       Dominant       6.50       0.40       -       -       -         15       Dominant       6.50       0.40       -       -       -       -         15       Dominant       6.50       0.40       Suppressio	6				30	Suppression	Null	5	73
Amblyopic       3.75       0.30		5 1							74
8         Dominant         5.88         0.00         4         Diplopia         Null         4           9         Dominant         1.25         0.00         2         Suppression         Null         5           10         Dominant         1.25         0.70         2         Suppression         Null         5           11         Dominant         0.63         0.10         4         Suppression         Null         5           12         Dominant         3.13         0.00         4         Suppression         Null         5           12         Dominant         7.50         0.00         35         Diplopia         Null         4           13         Dominant         6.50         0.00         30         Suppression         Null         5           14         Dominant         5.50         0.40         3         Suppression         Null         5           15         Dominant         5.50         0.40         3         Suppression         Null         5           16         Dominant         0.88         0.00         4         Suppression         Null         5           17         Dominant         2.0	7	Dominant	2.50		5	Suppression	Null	5	75
Amblyopic         5.50         0.40         Jump         Jump		Amblyopic	3.75	0.30					76
9         Dominant Amblyopic         1.25 3.25         0.00 0.02         2         Suppression Suppression         Null         5           10         Dominant         1.50         0.02         2         Suppression         Null         5           11         Dominant         0.63         0.10         4         Suppression         Null         5           11         Dominant         0.63         0.10         4         Suppression         Null         5           12         Dominant         3.13         0.00         4         Suppression         Null         4           13         Dominant         7.50         0.00         35         Diplopia         Null         4           14         Dominant         6.50         0.40         -         -         -           15         Dominant         5.50         0.30         Suppression         Null         5           16         Dominant         0.88         0.00         4         Suppression         Null         5           17         Dominant         3.63         -0.52         -         -         -         -           18         Dominant         2.05         0.30	8	Dominant	5.88	0.00	4	Diplopia	Null	4	77
Johnmant         1.23         0.00         2 suppression         Null         3           10         Dominant         1.50         0.02         2         Suppression         Null         5           11         Dominant         0.63         0.10         4         Suppression         Null         5           12         Dominant         3.13         0.00         4         Suppression         Null         5           13         Dominant         7.50         0.00         35         Diplopia         Null         4           Amblyopic         7.63         0.40		Amblyopic	5.50	0.40					78
10       Dominant       1.50       0.02       2       Suppression       Null       5         11       Dominant       0.63       0.10       4       Suppression       Null       5         11       Dominant       0.63       0.10       4       Suppression       Null       5         12       Dominant       3.13       0.00       4       Suppression       Null       5         13       Dominant       7.50       0.00       35       Diplopia       Null       4         14       Dominant       6.50       0.00       30       Suppression       Null       5         14       Dominant       6.50       0.40	9	Dominant	1.25	0.00	2	Suppression	Null	5	79
10       Dominant       1.50       0.02       2       Suppression       Null       5         Amblyopic       4.25       0.70		Amblyopic	3.25	0.70					80
Amblyopic       4.25       0.70         11       Dominant       0.63       0.10       4       Suppression       Null       5         12       Dominant       3.13       0.00       4       Suppression       Null       5         13       Dominant       7.50       0.00       35       Diplopia       Null       4         14       Dominant       6.50       0.40       Null       5       8         14       Dominant       5.50       0.40       Null       5       8         15       Dominant       5.50       0.40       Null       5       9         15       Dominant       5.50       0.30       Suppression       Null       5         16       Dominant       0.88       0.00       4       Suppression       Null       5         17       Dominant       3.63       -52       100       10       120       3.08         18       Dominant       2.75       -0.04       0       Fusion       1,200       3.08         19       Dominant       3.75       0.00       0       Suppression       Null       5         Amblyopic       5.50	10	Dominant	1.50	0.02	2	Suppression	Null	5	81
11       Dominant       0.63       0.10       4       Suppression       Null       5         12       Dominant       3.13       0.00       4       Suppression       Null       5         13       Dominant       7.50       0.00       35       Diplopia       Null       4         14       Dominant       6.50       0.00       30       Suppression       Null       5         14       Dominant       6.50       0.40       -       -       -       -         15       Dominant       5.50       0.40       -       -       -       -         15       Dominant       5.50       0.30       -       -       -       -       -         16       Dominant       0.88       0.00       4       Suppression       Null       5         17       Dominant       3.63       -52       -			4.25						82
Amblyopic       0.88       0.70         12       Dominant       3.13       0.00       4       Suppression       Null       5         13       Dominant       7.50       0.00       35       Diplopia       Null       4         14       Dominant       6.50       0.40	11	5 1			4	Suppression	Null	5	83
12       Dominant       3.13       0.00       4       Suppression       Null       5         13       Dominant       7.50       0.00       35       Diplopia       Null       4         14       Dominant       6.50       0.00       30       Suppression       Null       5         14       Dominant       6.50       0.40       Null       5       8         15       Dominant       5.50       0.40       Null       5       9         15       Dominant       5.50       0.30       Suppression       Null       5         16       Dominant       0.88       0.00       4       Suppression       Null       5         16       Dominant       3.63       -52       1       1       1       5       9         17       Dominant       3.63       -52       1       1       1       5       1       1       1       5       1       1       1       1       5       1 </td <td>••</td> <td></td> <td></td> <td></td> <td></td> <td>Suppression</td> <td></td> <td>5</td> <td>84</td>	••					Suppression		5	84
Amblyopic       4.38       0.70         13       Dominant       7.50       0.00       35       Diplopia       Null       4         14       Dominant       6.50       0.00       30       Suppression       Null       5         15       Dominant       5.50       0.00       30       Suppression       Null       5         16       Dominant       0.88       0.00       4       Suppression       Null       5         17       Dominant       3.63       -0.08       2       Suppression       Null       5         18       Dominant       3.63       -0.08       2       Suppression       Null       5         18       Dominant       2.00       0.00       4       Suppression       Null       5         19       Dominant       2.07       0.40       Fusion       1,200       3.08         11       Dominant       2.75       -0.04       0       Fusion       1,200       3.08         19       Dominant       3.75       0.00       0       Suppression       Null       5         11       Dominant       6.50       0.40       Upression       Null	12	5 1			Л	Suppression	Null	5	85
13       Dominant       7.50       0.00       35       Diplopia       Null       4         14       Dominant       6.50       0.00       30       Suppression       Null       5         14       Dominant       6.50       0.40       -       -       -         15       Dominant       5.50       0.00       30       Suppression       Null       5         16       Dominant       0.88       0.00       4       Suppression       Null       5         16       Dominant       0.88       0.00       4       Suppression       Null       5         17       Dominant       3.63       -0.08       2       Suppression       Null       5         18       Dominant       2.00       0.00       4       Suppression       Null       5         19       Dominant       2.75       -0.04       Fusion       1,200       3.08         Amblyopic       3.00       0.20       -       -       -       -         19       Dominant       3.75       0.00       0       Suppression       Null       5         Amblyopic       5.50       0.30       -       -	12				4	Suppression	Null	J	
Amblyopic       7.63       0.40         14       Dominant       6.50       0.00       30       Suppression       Null       5         15       Dominant       5.50       0.00       30       Suppression       Null       5         16       Dominant       0.88       0.00       4       Suppression       Null       5         16       Dominant       0.88       0.00       4       Suppression       Null       5         17       Dominant       3.63       -0.08       2       Suppression       Null       5         17       Dominant       3.63       -0.08       2       Suppression       Null       5         18       Dominant       2.00       0.00       4       Suppression       Null       5         18       Dominant       2.75       0.40       Fusion       1,200       3.08         19       Dominant       2.75       0.40       Fusion       1,200       3.08         19       Dominant       3.75       0.00       0       Suppression       Null       5         20       Dominant       5.50       0.20       Null       5         21 <td>47</td> <td>5 1</td> <td></td> <td></td> <td>25</td> <td>Dislasia</td> <td>NUU</td> <td>4</td> <td></td>	47	5 1			25	Dislasia	NUU	4	
14       Dominant       6.50       0.40       30       Suppression       Null       5         15       Dominant       5.50       0.40       30       Suppression       Null       5         16       Dominant       0.88       0.00       4       Suppression       Null       5         16       Dominant       0.88       0.00       4       Suppression       Null       5         17       Dominant       3.63       -0.08       2       Suppression       Null       5         17       Dominant       3.63       -0.08       2       Suppression       Null       5         18       Dominant       2.00       0.00       4       Suppression       Null       5         19       Dominant       2.75       -0.04       0       Fusion       1,200       3.08         11       Dominant       2.75       -0.04       0       Suppression       Null       5         20       Dominant       3.75       0.00       0       Suppression       Null       5         21       Dominant       6.50       0.40       -       -       2         22       Dominant	13				35	Біріоріа	NUII	4	
14       Dominant       6.50       0.40       30       Suppression       Null       5         4mblyopic       6.50       0.40       30       Suppression       Null       5         15       Dominant       5.50       0.30       -       -       -       -         16       Dominant       0.88       0.00       4       Suppression       Null       5       9         17       Dominant       3.63       -0.08       2       Suppression       Null       5       9         18       Dominant       2.00       0.00       4       Suppression       Null       5       9         19       Dominant       2.75       0.40       Fusion       1,200       3.08       1         19       Dominant       3.75       0.00       0       Suppression       Null       5         20       Dominant       6.50       0.40       Suppression       Null       5         21       Dominant       6.50       0.00       0       Suppression       Null       4         22       Dominant       5.00       0.20       -       -       -         22       Dominant		5 1			~ ~	- ·		_	90
Ambiyopic       6.50       0.40         15       Dominant       5.50       0.30         16       Dominant       0.88       0.00       4       Suppression       Null       5         17       Dominant       3.63       -0.08       2       Suppression       Null       5         17       Dominant       3.63       -0.08       2       Suppression       Null       5         18       Dominant       2.00       0.00       4       Suppression       Null       5         18       Dominant       2.00       0.00       4       Suppression       Null       5         19       Dominant       2.75       0.40       -       -       -       -         19       Dominant       2.75       -0.04       0       Fusion       1,200       3.08         Amblyopic       3.00       0.20       -       -       -       -         20       Dominant       3.75       0.00       0       Suppression       Null       5         21       Dominant       6.50       0.40       -       -       -       -         22       Dominant       5.00       0.	14				30	Suppression	Null	5	91
15         Dominant         5.50         0.00         30         Suppression         Null         5           Amblyopic         5.50         0.30         4         Suppression         Null         5         9           16         Dominant         0.88         0.00         4         Suppression         Null         5         9           17         Dominant         3.63         -0.08         2         Suppression         Null         5         9           18         Dominant         2.00         0.00         4         Suppression         Null         5         9           18         Dominant         2.00         0.00         4         Suppression         Null         5           19         Dominant         2.75         0.40         Fusion         1,200         3.08         1           19         Dominant         3.75         0.00         0         Suppression         Null         5           20         Dominant         3.75         0.00         0         Suppression         Null         5           21         Dominant         6.50         0.40         Diplopia         Null         4           22		5 1							92
Amblyopic       5.50       0.30         16       Dominant       0.88       0.00       4       Suppression       Null       5         17       Dominant       3.63       -0.08       2       Suppression       Null       5         17       Dominant       3.63       -0.08       2       Suppression       Null       5         18       Dominant       2.00       0.00       4       Suppression       Null       5         19       Dominant       2.75       0.40       -       -       -       -         19       Dominant       2.75       -0.04       0       Fusion       1,200       3.08         20       Dominant       3.75       0.00       0       Suppression       Null       5         21       Dominant       6.50       0.40       -       -       -       -         22       Dominant       6.50       0.40       -       -       -       -         22       Dominant       5.00       -0.04       0       Diplopia       Null       4         23       Dominant       5.00       0.20       -       -       - <t< td=""><td>15</td><td></td><td></td><td></td><td>30</td><td>Suppression</td><td>Null</td><td>5</td><td>93</td></t<>	15				30	Suppression	Null	5	93
16       Dominant       0.88       0.00       4       Suppression       Null       5       9         Amblyopic       1.00       0.40       0.40       5       9         17       Dominant       3.63       -0.08       2       Suppression       Null       5       9         18       Dominant       2.00       0.00       4       Suppression       Null       5       9         19       Dominant       2.75       0.40       0       Fusion       1,200       3.08       1         20       Dominant       2.75       -0.04       0       Fusion       1,200       3.08       1         19       Dominant       2.75       -0.04       0       Fusion       1,200       3.08       1         20       Dominant       3.75       0.00       0       Suppression       Null       5       1         4       Dominant       6.50       0.40       0       Suppression       Null       4       1         21       Dominant       5.00       -0.04       0       Diplopia       Null       4       1         22       Dominant       2.63       0.00       0		5 1	5.50						94
Amblyopic       1.00       0.40       9         17       Dominant       3.63       -0.08       2       Suppression       Null       5       9         18       Dominant       2.00       0.00       4       Suppression       Null       5       9         18       Dominant       2.00       0.00       4       Suppression       Null       5       9         19       Dominant       2.75       0.40       0       Fusion       1,200       3.08       1         20       Dominant       2.75       -0.04       0       Fusion       Null       5       9         20       Dominant       2.75       -0.04       0       Fusion       1,200       3.08       1         21       Dominant       3.75       0.00       0       Suppression       Null       5       1         22       Dominant       6.50       0.00       0       Suppression       Null       4       1         23       Dominant       5.00       -0.04       0       Diplopia       Null       5       1         24       Dominant       2.63       0.50       -       -       -	16	Dominant	0.88	0.00	4	Suppression	Null	5	95
Amblyopic       3.63       0.52       9         18       Dominant       2.00       0.00       4       Suppression       Null       5       9         19       Dominant       2.75       0.40       0       Fusion       1,200       3.08       1         19       Dominant       2.75       -0.04       0       Fusion       1,200       3.08       1         20       Dominant       3.75       0.00       0       Suppression       Null       5       1         21       Dominant       6.50       0.30       0       Suppression       Null       5       1         22       Dominant       6.50       0.00       0       Suppression       Null       4       1         23       Dominant       5.00       -0.04       0       Diplopia       Null       4       1         24       Dominant       2.63       0.00       0       Suppression       Null       4       1         25       Dominant       3.50       0.00       0       Suppression       Null       4       1         24       Dominant       3.50       0.00       0       Diplopia       Nul		Amblyopic	1.00	0.40					96
18       Dominant       2.00       0.00       4       Suppression       Null       5       9         19       Dominant       2.75       0.40       0       Fusion       1,200       3.08         19       Dominant       2.75       -0.04       0       Fusion       1,200       3.08         20       Dominant       3.75       0.00       0       Suppression       Null       5         21       Dominant       6.50       0.00       0       Suppression       Null       5         21       Dominant       6.50       0.40       0       Suppression       Null       5         22       Dominant       5.00       -0.04       0       Diplopia       Null       4         Amblyopic       5.50       0.20       0.20       0       Suppression       Null       4         23       Dominant       2.63       0.50       0.20       1       1         24       Dominant       3.50       0.00       0       Suppression       Null       4         4       Dominant       3.50       0.50       0.50       1       1         25       Dominant       8.50	17	Dominant	3.63	-0.08	2	Suppression	Null	5	97
Amblyopic       2.75       0.40       1         19       Dominant       2.75       -0.04       0       Fusion       1,200       3.08         20       Dominant       3.75       0.00       0       Suppression       Null       5         20       Dominant       3.75       0.00       0       Suppression       Null       5         21       Dominant       6.50       0.00       0       Suppression       Null       5         22       Dominant       5.00       -0.04       0       Diplopica       Null       4         Amblyopic       6.50       0.40       -       -       -       -         23       Dominant       2.63       0.00       0       Suppression       Null       4         Amblyopic       2.63       0.50       -       -       -       -         24       Dominant       3.50       0.00       0       Suppression       Null       4         4       Amblyopic       2.63       0.50       -       -       -       -         25       Dominant       8.50       0.10       0       Suppression       Null       5       - <td></td> <td>Amblyopic</td> <td>3.63</td> <td>0.52</td> <td></td> <td></td> <td></td> <td></td> <td>98</td>		Amblyopic	3.63	0.52					98
Amblyopic       2.75       0.40       1         19       Dominant       2.75       -0.04       0       Fusion       1,200       3.08         20       Dominant       3.75       0.00       0       Suppression       Null       5         20       Dominant       3.75       0.00       0       Suppression       Null       5         21       Dominant       6.50       0.00       0       Suppression       Null       5         22       Dominant       5.00       -0.04       0       Diplopica       Null       4         Amblyopic       6.50       0.40       -       -       -       -         23       Dominant       2.63       0.00       0       Suppression       Null       4         Amblyopic       2.63       0.50       -       -       -       -         24       Dominant       3.50       0.00       0       Suppression       Null       4         25       Dominant       3.50       0.50       -       -       -       -         25       Dominant       8.50       0.10       0       Suppression       Null       5       - <td>18</td> <td>Dominant</td> <td>2.00</td> <td>0.00</td> <td>4</td> <td>Suppression</td> <td>Null</td> <td>5</td> <td>99</td>	18	Dominant	2.00	0.00	4	Suppression	Null	5	99
19       Dominant       2.75       -0.04       0       Fusion       1,200       3.08         20       Dominant       3.75       0.00       0       Suppression       Null       5         20       Dominant       3.75       0.00       0       Suppression       Null       5         21       Dominant       6.50       0.00       0       Suppression       Null       5         22       Dominant       5.00       -0.04       0       Diplopia       Null       4         22       Dominant       5.00       -0.04       0       Diplopia       Null       4         23       Dominant       2.63       0.00       0       Suppression       Null       5         24       Dominant       3.50       0.00       0       Suppression       Null       4         25       Dominant       3.50       0.00       0       Diplopia       Null       5         25       Dominant       8.50       0.10       0       Suppression       Null       5		Amblyopic	2.75	0.40					10
Amblyopic       3.00       0.20         20       Dominant       3.75       0.00       0       Suppression       Null       5         21       Dominant       6.50       0.30       0       Suppression       Null       5         21       Dominant       6.50       0.00       0       Suppression       Null       5         21       Dominant       6.50       0.40       0       Suppression       Null       5         22       Dominant       5.00       -0.04       0       Diplopia       Null       4         Amblyopic       5.50       0.20       -       -       -       -         23       Dominant       2.63       0.00       0       Suppression       Null       5         24       Dominant       3.50       0.00       0       Suppression       Null       4         Amblyopic       2.63       0.50       -       -       -       -         24       Dominant       3.50       0.50       -       -       -       -         25       Dominant       8.50       0.10       0       Suppression       Null       5	19				0	Fusion	1,200	3.08	10
20       Dominant       3.75       0.00       0       Suppression       Null       5         Amblyopic       5.50       0.30       0       Suppression       Null       5         21       Dominant       6.50       0.00       0       Suppression       Null       5         22       Dominant       5.00       -0.04       0       Diplopia       Null       4         23       Dominant       2.63       0.00       0       Suppression       Null       5         24       Dominant       2.63       0.00       0       Suppression       Null       5         25       Dominant       8.50       0.10       0       Suppression       Null       4									102
Amblyopic       5.50       0.30         21       Dominant       6.50       0.00       0       Suppression       Null       5         22       Dominant       5.00       -0.04       0       Diplopia       Null       4         23       Dominant       2.63       0.00       0       Suppression       Null       5         24       Dominant       2.63       0.00       0       Suppression       Null       5         25       Dominant       3.50       0.00       0       Diplopia       Null       4         25       Dominant       8.50       0.10       0       Suppression       Null       5	20	5.			0	Suppression	Null	5	103
21       Dominant       6.50       0.00       0       Suppression       Null       5         Amblyopic       6.50       0.40       0       Diplopia       Null       4         22       Dominant       5.00       -0.04       0       Diplopia       Null       4         Amblyopic       5.50       0.20       0       Suppression       Null       5         23       Dominant       2.63       0.00       0       Suppression       Null       5         24       Dominant       3.50       0.00       0       Diplopia       Null       4         Amblyopic       5.50       0.50       0.50       0       1       1       4         Amblyopic       5.50       0.50       0.50       0       1       1       4         Amblyopic       5.50       0.50       0.50       0       1       1       5         25       Dominant       8.50       0.10       0       Suppression       Null       5					Ŭ			-	104
Amblyopic       6.50       0.40         22       Dominant       5.00       -0.04       0       Diplopia       Null       4         23       Dominant       2.63       0.00       0       Suppression       Null       5         24       Dominant       3.50       0.00       0       Diplopia       Null       4         25       Dominant       8.50       0.10       0       Suppression       Null       5	21				0	Sunnression	Null	5	10
22       Dominant       5.00       -0.04       0       Diplopia       Null       4         Amblyopic       5.50       0.20             23       Dominant       2.63       0.00       0       Suppression       Null       5         24       Dominant       3.50       0.00       0       Diplopia       Null       4         Amblyopic       5.50       0.50             24       Dominant       3.50       0.00       0       Diplopia       Null       4         Amblyopic       5.50       0.50              25       Dominant       8.50       0.10       0       Suppression       Null       5	21				0	Suppression	Null	5	10
Amblyopic       5.50       0.20         23       Dominant       2.63       0.00       0       Suppression       Null       5         24       Dominant       3.50       0.00       0       Diplopia       Null       4         24       Dominant       3.50       0.00       0       Diplopia       Null       4         25       Dominant       8.50       0.10       0       Suppression       Null       5	22				0	Diplopia	Null	1	10
23       Dominant       2.63       0.00       0       Suppression       Null       5       1         Amblyopic       2.63       0.50       1       1       1       1         24       Dominant       3.50       0.00       0       Diplopia       Null       4       1         Amblyopic       5.50       0.50       0.50       1       1       1       1         25       Dominant       8.50       0.10       0       Suppression       Null       5       1	22				0	Брюріа	NUII	4	108
Amblyopic         2.63         0.50         1           24         Dominant         3.50         0.00         0         Diplopia         Null         4         1           24         Dominant         5.50         0.50         5.50         0.50         1           25         Dominant         8.50         0.10         0         Suppression         Null         5         1		5.			~	<b>C</b>	N L . II	-	109
24         Dominant         3.50         0.00         0         Diplopia         Null         4         1           Amblyopic         5.50         0.50         1	23				0	Suppression	Null	5	11
Amblyopic         5.50         0.50         1           25         Dominant         8.50         0.10         0         Suppression         Null         5         1           1         1         1         1         1         1         1		5.							11
25 Dominant         8.50         0.10         0 Suppression         Null         5         1           1         <	24				0	Diplopia	Null	4	112
<b>1</b>									113
	25	Dominant	8.50	0.10	0	Suppression	Null	5	114
									11:

and hence the results of the treatment, Table 2. Refractive therapy outcomes. The BCVA is shown in logMAR acuity and ster-

116

117

No.	<b>Refraction SE</b>	BCVA	Δ	Worth Four-Dot test	Stereoacuity	BF
Amblyopic	8.88	0.30				
26 Dominant	3.63	0.10	0	Suppression	Null	5
Amblyopic	4.25	0.40				
				Visual Acuity, BF: Bin prismatic dioptres.	ocular Function	, DE:

#### Table 2. Continued

No.		Initial prismatic correction	BCVA	Worth Four- Dot test	Stereoacuity	BF
1	Dominant	10	0.00	Fusion	800	2.90
	Amblyopic		0.09			
2	Dominant	6	-0.04	Fusion	200	2.30
	Amblyopic		0.10			
3	Dominant	7	-0.04	Fusion	800	2.90
	Amblyopic		0.10			
4	Dominant	5	-0.04	Fusion	400	2.60
	Amblyopic		0.07			
5	Dominant	4	0.02	Fusion	800	2.90
	Amblyopic		0.02			
6	Dominant	32	-0.04	Fusion	800	2.90
	Amblyopic		-0.08			
7	Dominant	7	-0.04	Fusion	400	2.60
	Amblyopic		-0.08			
8	Dominant	6	0.07	Fusion	800	2.90
	Amblyopic		0.10			
9	Dominant	4	0.00	Fusion	200	2.30
	Amblyopic		0.10			
10	Dominant	4	0.00	Fusion	800	2.90
	Amblyopic		0.10			
11	Dominant	4	0.10	Fusion	800	2.90
	Amblyopic		0.10			
12	Dominant	6	0.00	Fusion	800	2.90
	Amblyopic		0.02			
13	Dominant	40	0.00	Fusion	400	2.60
	Amblyopic		0.07			
14	Dominant	32	0.00	Fusion	800	2.90
	Amblyopic		0.10			
15	Dominant	40	-0.04	Fusion	200	2.30
	Amblyopic		0.06			
16	Dominant	4	0.00	Fusion	400	2.60
	Amblyopic		0.05			
17	Dominant	6	0.05	Fusion	800	2.90
	Amblyopic		0.05			
18	Dominant	8	0.00	Fusion	400	2.60

Table 3. Outcomes after active therapy (prismatic correction and posterior vergence therapy) combined with occlusion (1–18). The subjects 6, 13–15 underwent strabismus surgery. The subjects 18-26 were treated only with occlusion therapy. The BCVA is shown in logMAR acuity and stereoacuity in second arc

preliminary step in patients with strabismic amblyopia.

Patients with fully accommodative esotropia resolved their amblyopia in a median of six months with spectacle correction and occlu-sion alone. In the partially accommodative esotropia group, the two passive treatments already described are not sufficient to restore binocular vision, which requires two more treatment phases: prismatic correction and posterior fusional vergence therapy. A number of studies have analysed the effect of prismatic correction on esotropia.<sup>32</sup> Although these stud-ies present good results in the acquisition of binocular vision, they offer no protocol of action to achieve binocular vision without pris-matic correction. 

The following study presents an interven-tion protocol that facilitates the restoration of binocular vision through prismatic correction and posterior fusional vergence therapy. With small-angle strabismus, the prismatic correction was able to be removed with fusional vergence therapy alone. However, where larger angles (>  $12\Delta$ ) were involved, strabismus surgery was necessary before the prisms could be removed. The sample size did not allow the comparison between the therapy and the surgical group; notwith-standing, all subjects in the surgical group achieved good outcomes in terms of residual angle (orthotropia) and fine stereoacuity. These good surgical results could be explained by the fact that the surgical angle of deviation was calculated according to a stable deviation angle, and this was possible thanks to the previous prismatic correction and visual therapy treatment. Prismatic correction was able to facilitate accurate calculation of the deviation before surgery. Fusional vergence therapy was able to pro-vide subjects a range of fusion around this angle. The PEDIG analysed the stability of subjects with partially accommodative esotropia in a longitudinal study,<sup>33</sup> finding that only 39 per cent of the sample had a stable deviation (that is, a variation  $\leq 5\Delta$ between measures). Birch et al.<sup>34</sup> con-cluded that subjects with accommodative esotropia and null stereopsis present greater instability in their angle of devia-tion, hence the acquisition of stereoacuity may stabilise the angle after surgery. 

The randomisation of this intervention protocol is not an option because subjects received one treatment or another according to their clinical characteristics, and no direct comparison between groups can be conducted, but differences between 

No.		Initial prismatic correction	BCVA	Worth Four- Dot test	Stereoacuity	BF
	Amblyopic		0.05			
19	Dominant	0	-0.04	Fusion	400	2.60
	Amblyopic		0.00			
20	Dominant	0	0.00	Fusion	400	2.60
	Amblyopic		0.10			
21	Dominant	0	0.00	Fusion	800	2.90
	Amblyopic		0.02			
22	Dominant	0	0.05	Fusion	200	2.30
	Amblyopic		0.05			
23	Dominant	0	0.00	Fusion	400	2.60
	Amblyopic		0.00			
24	Dominant	0	0.00	Fusion	400	2.60
	Amblyopic		0.06			
25	Dominant	0	0.10	Fusion	400	2.60
	Amblyopic		0.10			
26	Dominant	0	0.10	Fusion	200	2.30
	Amblyopic		0.10			
AE:	amblyopic ey	e, BCVA: Best Corre	ected Visu	ual Acuity, BF: E	inocular Functio	n, DE:

AE: amblyopic eye, BCVA: Best Corrected Visual Acuity, BF: Binocular Function, DE: dominant eye.

## Table 3. Continued

outcomes can be stated. Treatment duration in the fully accommodative esotropia group was longer than in the partially accommodative esotropia group, which combined both treatments. In addition, there were no significant differences in either BCVA or BF between the groups posttreatment. These findings indicate that the partially accommodative esotropia group achieved comparable values in a shorter period of time, despite being the more complex group at baseline, with lower BCVA and BF values; and suggest that active therapy could also be introduced in the fully accommodative esotropia group as a coadjutant to reduce occlusion times or shorten the treatment duration.<sup>35,36</sup> Dichoptic stimulation in serious games<sup>26,27</sup> or perceptual learning using Gabor patches<sup>37</sup> could also reduce the duration of treatments.

The present study is not exempt from limitations of sample selection, methodologies applied, or the absence of a control group. Subjects with near-distance incomitance (where the difference in the esotropia angle at near-distance fixation > 5 $\Delta$ ) were excluded from the sample, thereby facilitating the treatment of accommodative esotropia with single lenses. It is known that optical correction with bifocal lenses is necessary in cases of high AC/A ratio,<sup>38</sup> and it would be interesting in future studies to study whether the proposed treatment is also effective for this type of population.

Regarding the methodology, all the materials employed are well known in the literature and clinical practice, with the exception of the BF index. BF value has recently been introduced to facilitate statistical analysis of binocular vision data. The index assigns a numerical score to the subject's binocular vision to facilitate the numerical quantification of subjects with unquantifiable or null stereopsis. The tool, used by many other authors for similar purposes, proved highly useful for quantifying improvements in stereopsis, although it is not without limitations. Practitioners are not yet familiarised with the use of the index: all tables therefore include Worth Four-Dot test and Randot Preschool test results as well as BF index values.

The present study was conducted without a control group, although the treatment outcomes were verified by an external evaluator (visual acuity resolved and stereoacuity achieved). However, better designed studies are needed to support this intervention protocol.

## Conclusion

An intervention protocol in which passive therapy (optical correction and occlusion)

was combined with an active therapy program (prismatic correction and posterior vergence therapy) obtained good results in terms of visual acuity and stereoacuity in subjects with esotropic amblyopia. In subjects with a strabismus angle indicative of surgery, prismatic correction before surgery allowed them to obtain orthotropia and stereoacuity, while subjects with small-angle strabismus obtained comparable results with prismatic correction and fusional vergence therapy.

60

61

62

63

64

65

66

67

68 69

70

71

72

73

Q4<sub>A</sub>

75

76

77

78

79

80

81

82

83

84

85

86

87

88

**\$**9

90

91

Q6-

94

95

96

97

98

99

100

02

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

Q7

#### REFERENCES

- Ciuffreda KJ, Levi DM, Amblyopia SA. *Basic and Clinical Aspects*. Butterworth-Heinemann, 1991. Holopigian K, Blake R, Greenwald MJ. Clinical suppression and amblyopia. *Invest Ophthalmol Vis Sci* 1988; 29: 51.
- 3. McKee SP, Levi DM, Movshon JA. The pattern of visual deficits in amblyopia. *J Vis* 2003; 3: 380–405.
- O'Connor AR, Birch EE, Anderson S et al. Relationship between binocular vision, visual acuity, and fine motor skills. *Optom Vis Sci* 2010; 87: 942–947.
- Webber AL, Wood JM, Gole GA et al. The effect of amblyopia on fine motor skills in children. *Invest Ophthalmol Vis Sci* 2008; 49: 594–603.
- Koklanis K, Georgievski Z, Brassington K et al. The prevalence of specific reading disability in an amblyopic population. A preliminary report. *Binocul Vis Strabismus Q* 2006; 21: 27–32.
- Stifter E, Burggasser G, Hirmann E et al. Monocular and binocular reading performance in children with microstrabismic amblyopia. *Br J Ophthalmol* 2005; 89: 1324–1329.
- Grant S, Suttle C, Melmoth DR et al. Age- and stereovision-dependent eye-hand coordination deficits in children with amblyopia and abnormal binocularity. *Invest Ophthalmol Vis Sci*; 55: 5687–57015.
- Niechwiej-Szwedo E, Goltz HC, Colpa L et al. Effects of reduced acuity and stereo acuity on saccades and reaching movements in adults with amblyopia and strabismus. *Invest Ophthalmol Vis Sci.* 2017; 58.
- Chen AM, Cotter SA. The Amblyopia treatment studies: implications for clinical practice. *Adv Ophthalmol Optom.* 2016; 1: 287–305.
- 11. Birch EE. Amblyopia and binocular vision. *Prog Retin Eye Res* 2013; 33: 67–84.
- Baker DH, Meese TS, Mansouri B et al. Binocular summation of contrast remains intact in Strabismic Amblyopia. Invest Opthalmol Vis Sci 2007; 48: 5332.
- Farivar R, Thompson B, Mansouri B et al. Interocular suppression in strabismic amblyopia results in an attenuated and delayed hemodynamic response function in early visual cortex. *J Vis* 2011; 11. https://doi. org/10.1167/11.14.16.
- Mansouri B, Thompson B, Hess RF. Intact binocular interaction in amblyopia: a new gateway to treatment of amblyopia. *Invest Ophthalmol Vis Sci* 2008; 49: 2594.
- Hess RF, Mansouri B, Thompson B. A new binocular approach to the treatment of amblyopia in adults well beyond the critical period of visual development. *Restor Neurol Neurosci* 2010; 28: 793–802.
- Li SL, Jost RM, Morale SE et al. A binocular iPad treatment for amblyopic children. *Eye (Lond)* 2014; 28: 1246–1253.
- Webber AL, Wood JM, Thompson B. Fine motor skills of children with Amblyopia improve following binocular treatment. *Invest Ophthalmol Vis Sci* 2016; 57: 4713–4720.
- Kelly KR, Jost RM, Wang YZ et al. Binocular outcomes following binocular treatment for childhood amblyopia. Invest Ophthalmol Vis Sci 2018: 59: 1221–1228.
- 19. Read JCA. Stereo vision and strabismus. *Eye* 2015; 29: 214–224.

- Choe HR, Yang HK, Hwang JM. Long-term outcomes of prismatic correction in partially accommodative esotropia. *PLoS One* 2019; 14: e0225654.
   Portela-Camino LA Martín-González S. Ruiz-Alcocer L
  - Portela-Camino JA, Martín-González S, Ruiz-Alcocer J et al. A random dot computer video game improves stereopsis. Optom Vis Sci 2018; 95: 523–535.

- Stetlepsis. Optimites Str 2016, 53: 523–535.
   Suttle CM. Active treatments for amblyopia: a review of the methods and evidence base. *Clin Exp Optom* 2010; 93: 287–299.
- Holmes JM, Kraker RT, Beck RW et al. A randomized trial of prescribed patching regimens for treatment of severe amblyopia in children. *Ophthalmology* 2003; 110: 2075–2087.
- 24. Wallace DK, Pediatric Eye Disease Investigator Group, Edwards AR et al. A randomized trial to evaluate
   2 hours of daily patching for strabismic and anisometropic amblyopia in children. *Ophthalmology* 2006; 113: 904–912.
- Hopkins KB, Lyon DW, Chu R. Sequence for In Office
   Vision Therapy for Office Based Vision Therapy
   Group. Office Vision Therapy Manual of Procedures.
   2008:7-10. [Cited dd mm yyyy.] Available at: https://
   public.jaeb.org/pedig/stdv/35

- Lyon DW, Hopkins K, Chu RH et al. Feasibility of a clinical trial of vision therapy for treatment of amblyopia. *Optom Vis Sci* 2013; 90: 475–481.
- Bagolini B. Sensorio-motorial anomalies in strabismus: (anomalous movements). Doc Ophthalmol 1976; 28: 23–41.
- Yun-chun Z, Longqian L. The management of childhood esotropia with hyperopia. *Curr Med Res Opin* 2011; 27: 731–735.
- Webber AL, Wood JM, Thompson B et al. From suppression to stereoacuity: a composite binocular function score for clinical research. *Ophthalmic Physiol Opt.* 2020; 39: 53–62.
- McGraw PV, Barrett BT, Ledgeway T. Optical treatment of strabismic amblyopia. Ophthalmic Physiol Opt 2019; 39: 309–312.
- Cotter SA, Foster NC, Holmes JM et al. Optical treatment of strabismic and combined strabismicanisometropic amblyopia. *Ophthalmology* 2012; 119: 150–158.
- Han SB, Hwang JM. Prismatic correction of residual esotropia of 20 prism dioptres or less after full hypermetropic correction. *Eye* 2009; 23: 2052–2055.

- Pediatric Eye Disease Investigator Group, Christiansen SP, Chandler DL et al. Instability of ocular alignment in childhood esotropia. *Ophthalmology* 2008; 115: 2266–2274.e4.
   60
- Birch EE, Stager DR, Berry P et al. Stereopsis and longterm stability of alignment in esotropia. J AAPOS 2004; 8: 146–150.
- Singh A, Sharma P, Saxena R. Evaluation of the role of monocular video game play as an adjuvant to occlusion therapy in the management of anisometropic amblyopia. J Pediatr Ophthalmol Strabismus 2017; 54: 244-249.
- Stewart CE, Moseley MJ, Stephens DA et al. Treatment dose-response in amblyopia therapy: the monitored occlusion treatment of Amblyopia study (MOTAS). *Invest Ophthalmol Vis Sci* 2004; 45: 3048–3054.
- Chen PL, Chen JT, Fu JJ et al. A pilot study of anisometropic amblyopia improved in adults and children by perceptual learning: an alternative treatment to patching. *Ophthalmic Physiol Opt* 2008; 28: 422–428.
- Wallace DK. Are bifocals necessary for children with high AC/A esotropia? *Ophthalmology* 2016; 123: 679–680.

